{"id": 779787904763695105, "geo": null, "lang": "en", "text": "RT @CRTeditor: New study of @TevaUSA's pridopidine drug showed slowed progression of #huntingtonsdisease. https://t.co/rtpQgWf6A3", "user": {"id": 183626808, "url": "http://t.co/PlXHLByVXo", "lang": "en", "name": "Teva Pharmaceuticals", "id_str": "183626808", "entities": {"url": {"urls": [{"url": "http://t.co/PlXHLByVXo", "indices": [0, 22], "display_url": "tevausa.com", "expanded_url": "http://www.tevausa.com"}]}, "description": {"urls": [{"url": "https://t.co/gsGkRP8J3A", "indices": [136, 159], "display_url": "ow.ly/UZcKg", "expanded_url": "http://ow.ly/UZcKg"}]}}, "location": "United States", "verified": false, "following": true, "protected": false, "time_zone": null, "created_at": "Fri Aug 27 13:45:33 +0000 2010", "utc_offset": null, "description": "Official Teva US Twitter feed. We don't just make medicines, we make a difference in people's lives. Managed by Corp Comms. Guidelines: https://t.co/gsGkRP8J3A", "geo_enabled": false, "screen_name": "TevaUSA", "listed_count": 108, "friends_count": 1167, "is_translator": false, "notifications": false, "statuses_count": 1799, "default_profile": false, "followers_count": 5772, "translator_type": "none", "favourites_count": 855, "profile_image_url": "http://pbs.twimg.com/profile_images/1114240566001315840/wwBtyZu1_normal.png", "profile_banner_url": "https://pbs.twimg.com/profile_banners/183626808/1517338835", "profile_link_color": "94D487", "profile_text_color": "000000", "follow_request_sent": false, "contributors_enabled": false, "has_extended_profile": false, "default_profile_image": false, "is_translation_enabled": false, "profile_background_tile": false, "profile_image_url_https": "https://pbs.twimg.com/profile_images/1114240566001315840/wwBtyZu1_normal.png", "profile_background_color": "94D487", "profile_sidebar_fill_color": "000000", "profile_background_image_url": "http://abs.twimg.com/images/themes/theme1/bg.png", "profile_sidebar_border_color": "000000", "profile_use_background_image": false, "profile_background_image_url_https": "https://abs.twimg.com/images/themes/theme1/bg.png"}, "place": null, "id_str": "779787904763695105", "source": "Twitter for iPhone", "entities": {"urls": [{"url": "https://t.co/rtpQgWf6A3", "indices": [106, 129], "display_url": "huntingtonsdiseasenews.com/2016/09/22/tev\u2026", "expanded_url": "http://huntingtonsdiseasenews.com/2016/09/22/teva-phase-2-study-pridopidine-huntington-disease-finds-slower-disease-progression/"}], "symbols": [], "hashtags": [{"text": "huntingtonsdisease", "indices": [85, 104]}], "user_mentions": [{"id": 3153753120, "name": "Laurie Watanabe", "id_str": "3153753120", "indices": [3, 13], "screen_name": "CRTeditor"}, {"id": 183626808, "name": "Teva Pharmaceuticals", "id_str": "183626808", "indices": [28, 36], "screen_name": "TevaUSA"}]}, "favorited": false, "retweeted": false, "truncated": false, "created_at": "Sat Sep 24 21:01:38 +0000 2016", "coordinates": null, "contributors": null, "retweet_count": 2, "favorite_count": 0, "is_quote_status": false, "retweeted_status": {"id": 779462255603617792, "geo": null, "lang": "en", "text": "New study of @TevaUSA's pridopidine drug showed slowed progression of #huntingtonsdisease. https://t.co/rtpQgWf6A3", "user": {"id": 3153753120, "url": "http://t.co/ZiQduYTrxu", "lang": "en", "name": "Laurie Watanabe", "id_str": "3153753120", "entities": {"url": {"urls": [{"url": "http://t.co/ZiQduYTrxu", "indices": [0, 22], "display_url": "mobilitymgmt.com", "expanded_url": "http://mobilitymgmt.com"}]}, "description": {"urls": []}}, "location": "Irvine, California", "verified": false, "following": false, "protected": false, "time_zone": null, "created_at": "Mon Apr 13 22:17:59 +0000 2015", "utc_offset": null, "description": "Editor of Mobility Management, focusing on assistive technology for people with disabilities. Fan of ATPs, OTs and PTs. Views are my own.", "geo_enabled": false, "screen_name": "CRTeditor", "listed_count": 19, "friends_count": 175, "is_translator": false, "notifications": false, "statuses_count": 2205, "default_profile": false, "followers_count": 648, "translator_type": "none", "favourites_count": 903, "profile_image_url": "http://pbs.twimg.com/profile_images/587745327773429761/Cmm8INQr_normal.jpg", "profile_banner_url": "https://pbs.twimg.com/profile_banners/3153753120/1490114055", "profile_link_color": "3B94D9", "profile_text_color": "000000", "follow_request_sent": false, "contributors_enabled": false, "has_extended_profile": false, "default_profile_image": false, "is_translation_enabled": false, "profile_background_tile": false, "profile_image_url_https": "https://pbs.twimg.com/profile_images/587745327773429761/Cmm8INQr_normal.jpg", "profile_background_color": "000000", "profile_sidebar_fill_color": "000000", "profile_background_image_url": "http://abs.twimg.com/images/themes/theme1/bg.png", "profile_sidebar_border_color": "000000", "profile_use_background_image": false, "profile_background_image_url_https": "https://abs.twimg.com/images/themes/theme1/bg.png"}, "place": null, "id_str": "779462255603617792", "source": "Twitter Web Client", "entities": {"urls": [{"url": "https://t.co/rtpQgWf6A3", "indices": [91, 114], "display_url": "huntingtonsdiseasenews.com/2016/09/22/tev\u2026", "expanded_url": "http://huntingtonsdiseasenews.com/2016/09/22/teva-phase-2-study-pridopidine-huntington-disease-finds-slower-disease-progression/"}], "symbols": [], "hashtags": [{"text": "huntingtonsdisease", "indices": [70, 89]}], "user_mentions": [{"id": 183626808, "name": "Teva Pharmaceuticals", "id_str": "183626808", "indices": [13, 21], "screen_name": "TevaUSA"}]}, "favorited": false, "retweeted": false, "truncated": false, "created_at": "Fri Sep 23 23:27:38 +0000 2016", "coordinates": null, "contributors": null, "retweet_count": 2, "favorite_count": 1, "is_quote_status": false, "possibly_sensitive": false, "in_reply_to_user_id": null, "in_reply_to_status_id": null, "in_reply_to_screen_name": null, "in_reply_to_user_id_str": null, "in_reply_to_status_id_str": null}, "possibly_sensitive": false, "in_reply_to_user_id": null, "in_reply_to_status_id": null, "in_reply_to_screen_name": null, "in_reply_to_user_id_str": null, "in_reply_to_status_id_str": null}